Equity Profile

GRFS

Grifols, S.A.

Health CareBiotechnology$5.2B

Feb28Mon

Pre-Earnings Brief

UpcomingQ3-2021After Close9:00 AM EST

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines....

Key Metrics to Watch

Revenue Growth

Investors will be keen to see how Grifols' revenue has changed, especially given the ongoing demand for healthcare products.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and any deviation from expectations could significantly impact stock performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines. With a market cap of $5 billion, it plays a crucial role in the biotechnology sector, focusing on therapies for patients with rare diseases and other medical conditions.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

In the last quarter, Grifols reported an EPS of $0.24, falling short of expectations by 12.26%. The stock reacted positively, gaining 1.76% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Grifols are mixed, with uncertainty surrounding revenue and profitability. Investors will be watching closely for any signs of recovery or growth.

Bull Case

If Grifols can demonstrate strong demand for its plasma products and achieve better-than-expected EPS, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company reports disappointing earnings or reveals challenges in meeting demand, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue from plasma-derived products this quarter?

This figure will indicate the company's ability to meet market demand and could significantly influence investor sentiment.

How does management plan to address the recent EPS shortfall?

Understanding the company's strategy for improving profitability will be crucial for assessing future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Grifols to recover from its recent earnings miss, as demand for plasma products remains robust despite challenges.

Supporting Evidence

Options are pricing a 6.1% move, indicating expectations of volatility that may not align with the company's actual performance.

The historical average move has been only 1.52%, suggesting that the options market may be overestimating the potential for significant changes.

Key Risk

If plasma product demand exceeds expectations, it could significantly alter the market's perception of Grifols' growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Grifols' ability to recover from recent earnings misses and demonstrate growth.

Bull Confirmed If

A revenue growth rate of over 10% would confirm the bull case, indicating strong demand for products.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case, suggesting ongoing profitability challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±6.1%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around 1.35%, indicating negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the demand for plasma-derived therapies.
2Management's strategy to improve profitability following the EPS miss.
3Insights into competitive pressures in the biotechnology sector.
4Details on any new product launches or developments.
5Comments on market trends affecting the healthcare industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb25

DHILReported

Diamond Hill Investment Group, Inc.

RecapView

Feb28

JLLReported

Company Snapshot

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines....

Key Metrics to Watch

Revenue Growth

Investors will be keen to see how Grifols' revenue has changed, especially given the ongoing demand for healthcare products.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability, and any deviation from expectations could significantly impact stock performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GRFS Q3-2021 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

14%

Avg EPS Surprise

-3.86%

Avg Stock Reaction

+1.41%

Last Quarter Recap

In the last quarter, Grifols reported an EPS of $0.24, falling short of expectations by 12.26%. The stock reacted positively, gaining 1.76% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Grifols are mixed, with uncertainty surrounding revenue and profitability. Investors will be watching closely for any signs of recovery or growth.

Bull Case

If Grifols can demonstrate strong demand for its plasma products and achieve better-than-expected EPS, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company reports disappointing earnings or reveals challenges in meeting demand, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue from plasma-derived products this quarter?

This figure will indicate the company's ability to meet market demand and could significantly influence investor sentiment.

How does management plan to address the recent EPS shortfall?

Understanding the company's strategy for improving profitability will be crucial for assessing future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Grifols to recover from its recent earnings miss, as demand for plasma products remains robust despite challenges.

Supporting Evidence

Options are pricing a 6.1% move, indicating expectations of volatility that may not align with the company's actual performance.

The historical average move has been only 1.52%, suggesting that the options market may be overestimating the potential for significant changes.

Key Risk

If plasma product demand exceeds expectations, it could significantly alter the market's perception of Grifols' growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Grifols' ability to recover from recent earnings misses and demonstrate growth.

Bull Confirmed If

A revenue growth rate of over 10% would confirm the bull case, indicating strong demand for products.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case, suggesting ongoing profitability challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±6.1%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±6.1% while GRFS has averaged ±1.5% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

35.6%

Calls (22K)P/C Ratio: 0.33Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Grifols beats expectations, history suggests a potential stock increase of around 0.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting ongoing uncertainty in the market.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around 1.35%, indicating negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the demand for plasma-derived therapies.
2Management's strategy to improve profitability following the EPS miss.
3Insights into competitive pressures in the biotechnology sector.
4Details on any new product launches or developments.
5Comments on market trends affecting the healthcare industry.